GlaxoSmithKline (GSK) China announced that its biopharmaceutical product, Belizumab for Injection, for adult lupus nephritis (LN), has been included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalogue (2023). Belizumab is the only biologic recommended by the Chinese guidelines, EULAR guidelines, and KDIGO guidelines, and has been approved by the Chinese National Medical Products Administration for the treatment of systemic lupus erythematosus. At present, the indications for adult and pediatric systemic lupus erythematosus and adult lupus nephritis approved in China have been included in the national medical insurance directory.